1. Co-delivery of PLGA nanoparticles loaded with rSAG1 antigen and TLR ligands: An efficient vaccine against chronic toxoplasmosis
- Author
-
Majid Golkar, Isabelle Dimier-Poisson, Mojgan Allahyari, Marie-Noëlle Mévélec, Pezhman Fard-Esfahani, Recombinant Protein Production Department, Pasteur Institute of Iran, Molecular Parasitology Laboratory, Institut Pasteur d'Iran, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), Department of Biochemistry, Infectiologie et Santé Publique (UMR ISP), Université de Tours (UT)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Réseau International des Instituts Pasteur (RIIP)-Institut Pasteur d'Iran, Réseau International des Instituts Pasteur (RIIP), and Université de Tours-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)
- Subjects
Protozoan Vaccines ,Protozoan Proteins ,Monophosphoryl Lipid A ,Antibodies, Protozoan ,Toxoplasma gondii ,Antigens, Protozoan ,macromolecular substances ,Ligands ,Microbiology ,03 medical and health sciences ,chemistry.chemical_compound ,Mice ,0302 clinical medicine ,Immune system ,Antigen ,Adjuvants, Immunologic ,medicine ,Animals ,[SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology ,030304 developmental biology ,0303 health sciences ,Mice, Inbred BALB C ,Imiquimod ,biology ,business.industry ,technology, industry, and agriculture ,medicine.disease ,biology.organism_classification ,Toxoplasmosis ,3. Good health ,Vaccination ,Poly (D ,PLGA ,Infectious Diseases ,Toxoplasmosis, Animal ,chemistry ,Monophosphoryl lipid A ,Immunology ,biology.protein ,Mice, Inbred CBA ,Nanoparticles ,l-lactide-co-glycolide) PLGA ,rSAG1 ,Antibody ,[SDV.IMM.VAC]Life Sciences [q-bio]/Immunology/Vaccinology ,business ,Toxoplasma ,030215 immunology - Abstract
International audience; Although vaccination is a promising approach for the control of toxoplasmosis, there is currently no commercially available human vaccine. Adjuvants such as delivery vehicles and immunomodulators are critical components of vaccine formulations. In this study, Poly (D, l-lactide-co-glycolide) (PLGA) nanoparticles were applied to serve as delivery system for both surface antigen-1 (SAG1), a candidate vaccine against toxoplasmosis and two TLR ligands, monophosphoryl lipid A (MPL) and imiquimod (IMQ), respectively. Compared to rSAG1 alone, CBA/J mice immunized with rSAG1-PLGA produced higher anti-SAG1 IgG antibodies titers. This response was increased by the co-administration of IMQ-PLGA (p < 0.01). Compared to IMQ-PLGA co-administration, MPL-PLGA co-administration further increased the humoral response (p < 0.01) and potentiated the Th1 humoral response. Compared to rSAG1 alone, rSAG1-PLGA, or rSAG1-PLGA mixed with IMQ-PLGA or MPL-PLGA similarly enhanced the cellular response characterized by the production of IFN-γ, IL-2, TNF-α and low levels of IL-5, indicating a Th1-biased immunity. The induced immune responses, led to significant brain cyst reductions (p < 0.01) after oral challenge with T. gondii cysts in mice immunized with either rSAG1-PLGA, rSAG1-PLGA + IMQ-PLGA, rSAG1-PLGA + MPL-PLGA formulations. Taken together the results indicated that PLGA nanoparticles could serve as a platform for dual-delivery of antigens and immunomodulators to provide efficacious vaccines against toxoplasmosis.
- Published
- 2022